Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE MOA: Abrocitinib Mechanism of Action in Atopic Dermatitis
NCT03915496Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (3 arms), sponsored by Pfizer. Primary endpoint: Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at 12 weeks. Started Jun 2020; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03915496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915496.